Celltrion’s Remsima SC Biosimilar Starts Strong In EU5 Countries
New Study Follows Approval For IBD Indications Last Year
Celltrion is capitalizing on the earlier strength of its intravenous Remsima formulation to make waves with its innovative subcutaneous version, according to the results of a new study sampling nearly 250 gastroenterologists in EU5 countries.
You may also be interested in...
Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.
Celltrion Healthcare was ultimately able to increase its revenue by 16.7%, with stronger growth expected in H2.
As it begins to roll out its Yuflyma higher-strength adalimumab biosimilar in Europe, Celltrion has reported positive one-year data from a Phase III trial for the 100mg/ml Humira rival.